Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07054684 · ClinicalTrials.gov registry record · Phase 1

Study of BHV-1400 in IgA Nephropathy

A Phase 1 study of IgA Nephropathy, sponsored by Biohaven Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
20
Enrollment target
12
Study locations

NCT07054684 is a Phase 1 study of IgA Nephropathy that is actively recruiting participants, run by Biohaven Therapeutics. The registered enrollment target is 20 participants, below the 165-participant average among 10 other IgA Nephropathy trials with a reported enrollment target (88% lower). The trial reports 12 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07054684, a Phase 1 study of IgA Nephropathy, is actively recruiting participants, sponsored by Biohaven Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target
12
Study locations

Study Summary

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Conditions Studied

IgA Nephropathy

Interventions

  • DRUG BHV-1400

Study Locations (12)

Florida

  • Site-003 - Miami Lakes
  • Site-011 - Miami Lakes
  • Site-013 - Orlando
  • Site-005 - Pembroke Pines

Connecticut

  • Site-001 - Farmington

Georgia

  • Site-008 - Lawrenceville

Illinois

  • Site-009 - Hinsdale

Indiana

  • Site-012 - Indianapolis

Missouri

  • Site-006 - Chesterfield

South Dakota

  • Site-002 - Dakota Dunes

Texas

  • Site-004 - Houston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-07-30
Est. Completion 2027-07
Phase Phase 1

Sponsor

Biohaven Therapeutics

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07054684

The ClinicalTrials.gov registry entry for NCT07054684 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 165-participant average among 10 other IgA Nephropathy trials with a reported enrollment target (88% lower). The listed sponsor is Biohaven Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with IgA Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which BHV-1400 is the first listed.

NCT07054684 reports 12 study locations spanning 9 distinct geographic areas - top geographies include Florida, Connecticut, Georgia.

Frequently Asked Questions

What is clinical trial NCT07054684 about?

NCT07054684 is a clinical study titled "Study of BHV-1400 in IgA Nephropathy". The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

What is the current status of trial NCT07054684?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-07-30. Estimated completion is 2027-07.

What conditions does trial NCT07054684 study?

This clinical trial studies the following conditions: IgA Nephropathy.

What interventions are being tested in trial NCT07054684?

The interventions under investigation include: BHV-1400 (DRUG).

Who is sponsoring clinical trial NCT07054684?

This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07054684 being conducted?

This trial has 12 study locations across Connecticut, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for IgA Nephropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

IgA Nephropathy

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.